Mergers And Acquisitions: Is There A Pending Catalyst For Crispr Therapeutics? – Seeking Alpha
Seeking Alpha |
Mergers And Acquisitions: Is There A Pending Catalyst For Crispr Therapeutics?
Seeking Alpha The aforementioned statement suggested that there's a favorable chance that Gilead is sizing up the following leading gene editing innovators for acquisition: CRISPR Therapeutics (NASDAQ:CRSP), Editas Medicine (NASDAQ:EDIT), Intellia Therapeutics … |
